Inflammatory bowel disease, colorectal cancer and type 2 diabetes mellitus: The links  by Jurjus, Abdo et al.
BBA Clinical 5 (2016) 16–24
Contents lists available at ScienceDirect
BBA Clinical
j ourna l homepage: www.e lsev ie r .com/ locate /bbac l inInﬂammatory bowel disease, colorectal cancer and type 2 diabetes
mellitus: The linksAbdo Jurjus a,b, Assad Eid a, Sahar Al Kattar a, Marie Noel Zeenny a, Alice Gerges-Geagea b, Hanine Haydar a,
Anis Hilal a, Doreid Oueidat a, Michel Matar b, Jihane Tawilah b, Inaya Hajj Hussein c,
Pierre Schembri-Wismayer d, Francesco Cappello e, Giovanni Tomasello e, Angelo Leone e, Rosalyn A. Jurjus f,⁎
a Department of Anatomy Cell Biology and Physiology, Faculty of Medicine, American University of Beirut, 1107-2020 Beirut, Lebanon
b Lebanese Health Society, Beirut, Lebanon
c Oakland University William Beaumont School of Medicine, Rochester, MI, USA
d Department of Anatomy, Faculty of Medicine and Surgery, University of Malta, Msida MSD06, Malta
e Department of Experimental and Clinical Neurosciences, University of Palermo, 90133, Italy
f Department of Anatomy and Regenerative Biology, Georges Washington University, Washington, DC 20037, USA⁎ Corresponding author at: Department of Anatomy and
NW, Washington, DC 20037, USA.
E-mail address: rajurjus@gwu.edu (R.A. Jurjus).
http://dx.doi.org/10.1016/j.bbacli.2015.11.002
2214-6474/© 2015 The Authors. Published by Elsevier B.Va b s t r a c ta r t i c l e i n f oArticle history:
Received 2 October 2015
Accepted 3 November 2015
Available online 5 November 2015
Keywords:
IBD
CRC
T2DM
Probiotic
Dysbiosis
InﬂammationThe co-occurrence of the three disease entities, inﬂammatory bowel disease (IBD), colorectal cancer (CRC), type
2diabetes mellitus (T2DM) along with inﬂammation and dismicrobism has been frequently reported. Some
authors have even suggested that dysbiosis could be the link through amolecular crosstalk ofmultiple inﬂamma-
tory loops including TGFβ, NFKB, TNFα and ROS among others.
This review focuses on the inﬂammatory process along with the role of microbiota in the pathophysiology of the
three diseases.
The etiology of IBD is multifactorial, and like CRC and T2DM, it is associated with a widespread and sustained GI
inﬂammation and dismicrobism, whereby an array of pro-inﬂammatory mediators and other related biomole-
cules are up-regulated, both locally and systematically. Such a persistent or an inadequately resolved chronic
inﬂammation may be a causative agent, in the presence other factors, leading to several pathologies such as
IBD, CRC and T2DM.
TGFβ plays a crucial role in pancreatic β cell malfunctioning as glucotoxicity stimulates its signaling cascade
through smad 3, IL-6 and epithelial to mesenchymal transition. Such a cascade could lead to macrophages and
other cells recruitment, inﬂammation, then IBD and CRC.
NFkB is also another key regulator in the crosstalk among the pathways leading to the three disease entities. It
plays a major role in linking inﬂammation to cancer development through its ability to up regulate several
inﬂammatory and tumor promoting cytokines like: IL-6, IL-1 α and TNF α, as well as genes like BCL2 and
BCLXL. It activates JAK/STAT signaling network via STAT3 transcription factors and promotes epithelial tomesen-
chymal transition. It also increases the risk for T2DM in obese people. In brief, NFKB is a matchmaker between
inﬂammation, IBD, cancer and diabetes.
In addition, TNFα plays a pivotal role in systemic inﬂammation. It is increased in the mucosa of IBD patients and
has a central role in its pathogenesis. It also activates other signaling pathways like NFKB and MAPK leading to
CRC. It is also overexpressed in the adipose tissues of obese patients thus linking it to T2DM, chronic inﬂammation
and consequently CRC.
On the other hand, increasing evidence suggests that dysbiosis plays a role in initiating, maintaining and deter-
mining the severity of IBD. Actually, among its functions, it modulates genotoxic metabolites which are able to
induce CRC, a fact proven to be sustained by stool transfer from patients with CRC. Probiotics, however, may
actively prevent CRC as well as IBD and results in a signiﬁcant decrease in fasting glycemia in T2DM patients.
In conclusion, IBD, CRC and T2DM are commonly occurring interrelated clinical problems. They share a common
basis inﬂuenced by an inﬂammatory process, an imbalance in intestinal microbiota, and a crosstalk between
various signaling pathways. Would probiotics interrupt the crosstalk or orient it in the physiological direction?
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Regenerative Biology, TheGeorgeWashingtonUniversity School ofMedicine andHealth Sciences, 461B RossHall, 2300 I Street,
. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The medical literature is depleting in publications reporting the co-
occurrence of the three disease entities: inﬂammatory bowel disease
(IBD), colorectal cancer (CRC) and type 2 diabetes mellitus (T2DM),
along with inﬂammation and dismicrobism [8,17,21,41,51]. Actually,
the body microbiota represents a complex ecosystem with enormous
microbial diversity. Trillions of bacterial cells colonize the GI surface
within the human body and can reach 10 times the number of the
cells forming thewhole organism. In addition; the genes of thesemicro-
organisms are 150 times higher in number than those in the human
body. Most of the commensal bacteria are symbiotic; however, they
could cause pathology after their translocation to the mucosa or under
speciﬁc conditions. The largest number of bacterial cells is found in
the large intestine (1011 per gram of intestinal content), themain geog-
raphy of IBD and CRC [19,41].
In general, intestinal dysbiosis is associated with an undesirable
qualitative and quantitative alteration in the balance between beneﬁcial
and harmful bacteria in the gut [17]. It is also well documented that
changes in the homeostasis of the intestinal microbiota have far-
reaching effects on local and systemic immunity and contribute to the
pathogenesis of gastrointestinal diseases like inﬂammatory bowel
disease, irritable bowel syndrome and colorectal cancer, as well as
extra intestinal systemic diseases like obesity, diabetes and atheroscle-
rosis among others [57]. Some authors have even suggested that
dysbiosis could be the link between chronic inﬂammation, IBD, CRC
and T2DM trough a crosstalk between several molecular pathways, in
particular, TGFβ, NFKB, TNFα and ROS among others [20]. The mecha-
nisms forming the basis of such a phenomenonwere referred to a series
of complex interactions between the intestinal epithelium, microbiota,
genetic factors, and the host immune system,whichmodulate the intes-
tinal equilibrium.
Normally, the intestinal epithelium has a critical function as a
protective barrier against luminal antigens. It is covered by a single
layer of intestinal epithelial cells (IECs) distinguished by a fast renewal
rate. They are circumferentially tied by intracellular tight junctions
and coated by a thick adherent mucus gel, thus forming a dynamic
physical interface between the host and its environment [35,62].
Despite its robust and multi-faced nature, this barrier can be breached,
hence disrupting the intestinal homeostasis, and thus promoting a
state of chronic inﬂammation in all these three disease entities: IBD,
T2DM and CRC [29].
Normally, inﬂammation is basically a beneﬁcial activity that
rejuvenates injured tissue and removes the foreign agents disturbing ho-
meostasis, thus leading to recovery of the equilibrium state. This task is
achieved through a complex inﬂammatory response which may involve
a balance between a huge panel of bioactive molecules, pro and anti-
inﬂammatory (IL-6, NFKB, TNFα and TGFβ, among others…), providedfrom resident or inﬁltrating inﬂammatory cells. However, a persistent
or an inadequately resolved chronic inﬂammation, due to the tilting of
the balance in favor of pro-inﬂammatory agents, may increase the risk
of several pathologies such as IBD, CRC and T2DM. How inﬂammation
lies on the causative pathwaymechanistically linking these three chronic
clinical problems remains unclear [43,13].
In this review, the focus is on the inﬂammation process as constitut-
ing the basis in the development of CRC, IBD and T2DM. Several molec-
ular signaling pathways involved in such inﬂammation like TGFβ, JAK/
STAT, TNFα, NFkB and ROS production mechanisms will be discussed,
along with the role of microbiota in the physiopathology of these
three diseases. Collectively, the molecular crosstalk between all of
these pathways could probably deﬁne the nature of the link or links
between all three disease entities.
2. Inﬂammatory bowel disease
IBD is an idiopathic, chronic, inﬂammatory disease that affects the
colon and other parts of the gastrointestinal tract. It may also have
extra-intestinal manifestations [20]. The exact etiology of IBD is unre-
vealed yet, but it is generally known to bemultifactorial, with the possi-
ble leading trigger as a disbalance of the luminal mucosal homeostasis
in genetically susceptible organisms [29,44]. Consequently, an altered
balance between regulatory and inﬂammatorymediators could contrib-
ute to an inappropriate and sustained inﬂammatory response probably
caused by a dysfunction of the microﬂoral integrity [17]. IBD encom-
passes a range of intestinal pathologies, the 2 major clinical entities
(ulcerative colitis (UC) and Crohn's disease (CD)) showoverlapping fea-
tures and a similar symptom proﬁle which can include; diarrhea, rectal
bleeding, abdominal pain and weight loss [34,23].
2.1. Crohn's disease (CD)
It is often associated with a widespread inﬂammation that can affect
any region of the intestine from the mouth to the anal canal but mostly
involves the ileum and the colon [59].
At the histological level, CD is characterized by the spread of lym-
phoid aggregates in the mucosa and submucosa layers of the bowel.
At the beginning of the disease, neutrophil inﬁltrates are observed in
the epithelial layer. As the disease progresses, neutrophils inﬁltrate
into the crypts. They form crypt abscesses, hence destroying the crypt
leading to colonic atrophy. Another observed feature resulting from
this chronic inﬂammation is the formation of non-necrotizing granulo-
mas. Ulcers constitute also a main feature of CD which enlarge and
may then develop into a network of long perforating ulcerations [46].
These microscopic changes ultimately lead to a series of complications
including: abdominal pain, diarrhea which is a common presentation
of CD, rectal bleeding, ﬁstula and perianal disease which are often very
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the terminal ileum (59).
The proﬁle of cytokines ruling the inﬂammation of Crohn's disease,
while well deﬁned, continues to be a work in progress. A Th17 response
is the main cause of Crohn's disease inﬂammation through the produc-
tion of IL-17 and IFN-γ. These are not, of course, the only cytokines
taking part in the CD inﬂammation, their downstream cytokines: TNF-
α, IL-6 and IL-1 play pivotal roles as the immediate effectors of inﬂam-
mation, in addition to several others including IL-22 [60].
2.2. Ulcerative colitis
UC is also an inﬂammatory disease featuring recurrent and chronic
inﬂammation of the colonic mucosa and submucosa [25]. It usually
begins in the rectum. Depending on the severity and the course of the
disease; it could extend to the proximal parts in a continuous fashion
[58]. In severe cases, acute dilatation of the colon, necrosis, perforation
and massive hemorrhage with the formation of pseudopolyps are clini-
cally manifested [19]. Histologically, UC can result in crypt abscesses
with neutrophils inﬁltrating the crypts. Moreover, in severe cases,
hypertrophy of the muscularis mucosa can occur which may lead to a
narrowing and shortening of the colon [46].
Typical symptoms of UC include rectal bleeding or bloody diarrhea
associated with abundant mucus discharge, abdominal pain, fever,
weight loss and malaise [19]. The presence of these symptoms and
their severity correlate with the activity of the disease [59]. The pre-
dominant cytokines in UC are mainly from the Th2 pattern of the
adaptive immune response which produces several pro-inﬂammatory
cytokines such as IL-4, IL-5 and IL-13 [41].
3. Diabetes mellitus
Diabetesmellitus (DM) is a chronic disease that is classiﬁed into two
major types: type 1 diabetes mellitus (T1DM) and type 2 diabetes
mellitus (T2DM). T2DM constitutes 90% of all diabetes and is a common
endocrine disorder. On the other hand, T1DM is an immunologically
mediated disorder. It is insulin-dependent diabetes whereby the body's
immune system destroys the βeta cells that release insulin and eventu-
ally eliminating insulin production from the body. However, in T2DM,
the body cannot use the insulin leading to insulin resistance [8].
Insulin resistance and β-cell dysfunction are considered as early and
critical components in the pathophysiology of T2DM. In addition, a
timely inﬂammatory process has been described with the up regulation
of growth factors like TGFβ and pro-inﬂammatory cytokines like IL-1β
and other biological molecules like ROS [18,50,51].
4. Colorectal cancer
It is well established that CRC originates from the epithelial cells
lining the colon or rectum of the gastrointestinal tract and represents
the third most common form of cancer worldwide [22]. Recently,
CRC incidence has been increasing along with its mortality rates. Mul-
tiplemolecular pathways intersect, thus probably promoting its occur-
rence. However, there is constantly an inﬂammatory reaction
persisting and maintained. Whereby, an array of pro-inﬂammatory
mediators is elevated both locally and systemically, such as; cyclooxy-
genase 2 (COX-2), prostaglandin E2 (PGE2), TNFα, NFkB, TGFβ among
others…. Despite the multiple factors responsible for its onset, its in-
cidence and prevalence increase more in patients with IBD and/or
T2DM [13,17,21].
5. TGFβ
TGF-β constitutes a common factor in all the three disease entities. It
is a multifunctional cytokine that plays an important role in the regula-
tion of many cellular pathways including cell growth, apoptosis,differentiation and immune reactions. Under normal conditions, TGF-
β is a strong anti-inﬂammatory cytokine exerting a suppressive effect
on carcinogenesis by inhibiting abnormal cell growth. The uncontrolled
cell growth and differentiation in many GI cancers are attributed to a
genetic loss of TGF-β signaling molecules and an alteration of TGF-β re-
ceptors. Once a tumor has developed, TGF-β will promote tumor cell
growth, enhance invasiveness and metastasis and inhibit immune
surveillance [51,53].
During the pathogenesis of T2DM, TGFβ plays a crucial role in β cell
malfunctioning, as glucotoxicity stimulates TGFβ signaling cascade,
moreover, glucotoxicity, which is the chronic exposure to hyperglyce-
mia, leads to reactive oxygen species (ROS) accumulation in pancreatic
β islets. As anti-oxidative enzymes are not sufﬁciently present in β cells,
ROS accumulation may result in oxidative stress, a well-known trigger
for β cells apoptosis [51] (Fig. 1). This oxidative stress, along with Free
Fatty Acids—FFAs—(secreted by stimulated adipocytes) abolishes
the normal function of β cells and induces the generation of pro-
inﬂammatory mediators, such as IL-1 β, TNFα and IL-6, thus causing
inﬂammation in pancreatic islets and peripheral tissues [36]. Conse-
quently, β cell dysfunctionmay lead to insulin resistance and disruption
of glucose homeostasis. Pro-inﬂammatory mediators, such as IL-1 β
binds IL-1 receptor (IL-1 R) and leads to NFkB activation, which will in-
teractwithmultiple signaling pathways, aswill be depicted later on [36,
51].
TGFβ and its related factors control the development, growth and
function of diverse cell types. It transmits its signals via dual serine/thre-
onine kinase receptors and transcription factors called smads, with
smad 3 acting as the main facilitator of TGFβ signaling [61]. Several
studies illustrate the role of TGFβ/smad3 signaling in the pathogenesis
of T2DM. In a study conducted byHariom et al. in 2011, smad 3 deﬁcient
micewere protected from diet-induced obesity and diabetes, while sys-
temic blockage of TGFβ signaling protects mice from diabetes and
hepatic steatosis [18]. TGFβ also induces adipocytes hypertrophy and
adipocytes produce FFAs. A prolonged exposure of FFAs to β cells in-
hibits insulin synthesis and promotes oxidative stress, leading eventual-
ly to insulin resistance [51] (Fig. 1).
Furthermore, the GI tract which is constantly exposed to various
pathogens and food antigens can induce a series of host defensive
reactions such as recruitment of immune cells, activation of anti-
inﬂammatory enzymes and secretion of anti-inﬂammatory cytokines.
Regulatory T (Treg) cells are among the various regulatorymechanisms
whose function is partly to maintain the gut barrier and other immune
reactions in order to prevent a pathological inﬂammation and maintain
GI tract homeostasis through tolerance. In addition IL-6, plays an impor-
tant role in inﬂammation, a key ﬁeld of action of IL-6 is the regulation of
T cell differentiation and activation. Numerous studies provided evi-
dence that IL-6 is a critical regulator of murine models of experimental
colitis. It was proven that IL-6 inhibition, decreases the multiplication
and size of colonic adenomas in Azoxymethane (AOM) and Dextran
sodium sulfate (DSS) mice models [52]. The key factor and regulator
of IL-6 in chronic intestinal inﬂammation works via th1 and th17 cells
[14]. IL-6, through its trans-signaling can also modulate epithelial
cells, neutrophils, macrophages and T cells. In addition, IL-6 promotes
the production of th17 cells and TGF-β and induces the maintenance
of IL-17 signaling T lymphocytes in inﬂamed tissues while it exerts a
suppressive effect on the generation of regulatory T cells (Treg). More-
over, IL-6 is an important factor for the synthesis of C-reactive protein
whose level is found to be elevated in acute and chronic inﬂammation.
Furthermore, IL-6 plays a potential role in the pathogenesis of diabetes
through mediating local inﬂammation and tissue destruction in a NOD
mouse model. It was also reported that IL-6R signaling blockage and
STAT-3 activation lead to a T cell apoptosis in lamina propria cells in cul-
ture [42]. Fig. 2 demonstrates that TGF β has a role in the pathogenesis
of IBD, and it also may contribute to the cancer risk associated with
chronic inﬂammation of the gut. TGF β in the presence of IL-6, which
is produced during active infections or other inﬂammatory states,
Fig. 1. The various interactions between TGFβ, Smad 3, IBD, T2DM and colon carcinogenesis are illustrated. Note that blue arrows indicate induction and stimulation, while red arrow
means disruption or inhibition.
19A. Jurjus et al. / BBA Clinical 5 (2016) 16–24leads to the differentiation of naïve T cells into Th-17 cells, a set of T
helper cells secreting IL-17, a potent inﬂammatory cytokine. The pro-
duction of IL-17 leads to chemokine expression such as IL-6 and TNFα
[30]. Th-17 appears to play an important role in IBD, and drives a pro-Fig. 2. TGF β creates a cancer-promoting feedback loop and is related through various patcarcinogenic process under poorly regulated pro-inﬂammatory condi-
tions [49] (Fig. 2).
TGFβ also contributes to epithelial to mesenchymal transition
(EMT), a hallmark that facilitates metastasis and invasion throughhways to IBD, CRC and T2DM. Note that blue arrows mean induction or stimulation.
20 A. Jurjus et al. / BBA Clinical 5 (2016) 16–24multiple signaling mechanisms, leading eventually to tight junctions
(TJ) and adherent junctions (AJ) dissolution. Another mechanism, by
which TGFβ facilitates EMT, is through the up regulation of metallopro-
teinases (MMPs), contributing to colon carcinogenesis and metastasis
[24] (Fig. 2).
In a study conducted by Hawinkels et al. in 2014, a strong activation
of TGF-β/Smad signaling pathway was observed in CRC. TGF-β1 stimu-
lation caused a remarkable up regulation of MMPs, plasminogen activa-
tor inhibitor-1 (PAI-1) and TGF-β1 itself, thus, leading to cumulative
production of TGF-β and proteinases within the tumor microenviron-
ment and consequently creating a cancer-promoting feedback loop
[32] (Fig. 2).
Actually, in IBD a battery of cytokines were described as being
secreted (TNFα, IL-6, IL-17, IL-27 among others), which contribute to
the formation of a tumor supporting microenvironment.
Macrophages, phagocytic cells of the innate immune system, are
essential not only for engulﬁng foreign agents that enter the body, but
also for eliminating apoptotic cells and digesting wastes from tissues.
The activity of macrophages can be increased by cytokines secreted by
helper T cells, especially IFN-γ. During inﬂammation, macrophages re-
lease a wide range of pro-inﬂammatory cytokines such as TNF-α, IL-6,
IL-8 and IL-12, in addition to the release of chemokines, prostaglandins
and complement. The interactions of all of thesemediators could lead to
an increased vascular permeability and recruitment of inﬂammatory
cytokines [26]. Consequently, environmental triggers like microbiota
and inﬂammation together can result in damage to the epithelial cells.
The increase in inﬂammatory cells and the factors they produce result
in oxidative stress, which can induce DNA damage resulting in genetic
and epigenetic alterations to the epithelial cells, thus causing dysplasia,
cancer and clonal expansion of these cells. The net result is disruption of
the balance of mediators with increase in TGFβ, IL-6 and TNFα among
others leading to IBD, CRC and consequently T2DM.
Among the different cytokines, IL-13 and IL-4 secreted by Th2 cells
have been shown to increase the colonic mutations in epithelial cells,
to support angiogenesis and to produce TGFβ. In addition, cytokinesFig. 3. The different effector cells recruited in IBD and their associated cytokines leading to a dis
stimulation and red color (circle and arrow) means mitogenic stimulation.secreted by Th-17 are proven to bemitogenic. Fig. 3 shows the different
effector cells recruited in IBD and their associated cytokines [16].
6. NFKB
There are several lines of evidence posing NFKB as a key regulator in
the crosstalk among the pathways leading to T2DM, CRC, and IBD. Actu-
ally, various carcinogens, growth factors, inﬂammatory stimuli includ-
ing microbiota and pro-oxidants activate the transcription factor NFkB
which plays a central role in inﬂammation and is mostly expressed in
cancers [37]. It was documented that NFkB is activated via phosphoryla-
tion of inhibitor of kappa B (IKB) leading to its ubiquitination and
proteasomal degradation. Such a reactionwill unmask the nuclear local-
ization signal of NF-KB, and once in the nucleus, it will activate several
genes that regulate proliferation, apoptosis, angiogenesis, invasion,
inﬂammation and metastasis [63,47] (Fig. 4).
NFKB plays a major role in linking chronic inﬂammation to cancer
development through its ability to up regulate several inﬂammatory,
and tumor promoting cytokines such as IL-6, IL-1α and TNF-α, as well
as survival genes such as BCL2 and BCLXL [63] (Fig. 4).
In a study conducted byGreten FR et al. in 2004, a crucial role for IKK
beta was demonstrated, linking inﬂammation to cancer in a mouse
model of colitis-associated cancer, deleting IKK beta in myeloid cells
resulted in a signiﬁcant decrease in tumor size. This deletion also dimin-
ished the expression of pro-inﬂammatory cytokines [12] (Fig. 4).
In addition, NFkB promotes EMT, through its activation of snail and
twist [5] in the microenvironment, and the expression of inﬂammatory
cytokines. Moreover, NFKB seems to be involved in the tumor associat-
ed macrophage (TAM) recruitment and acts in cancer-associated ﬁbro-
blasts (CAF), by promoting the expression of a pro-inﬂammatory gene
signature, which is important for macrophage recruitment, neovascu-
larization and tumor growth that were abolished when NFKB was
inhibited [1,40] (Fig. 4).
Furthermore, NFKB plays an important role in T2DM, as obesity
activates the transcription factor NFKB which increases the risk forbalance in pro and anti-inﬂammatory agents. Note that blue arrows indicate induction, or
Fig. 4. NFkB the matchmaker between, inﬂammation, IBD, CRC and T2DM and their wide mechanisms of action. Note that blue arrows mean induction or stimulation.
21A. Jurjus et al. / BBA Clinical 5 (2016) 16–24T2DM. It has been shown that NFKB pathway inhibition exerts a beneﬁ-
cial effect on T2DM, salsalate a prodrug that reduces NFkB activity was
shown to decrease HBA1C levels [38].Fig. 5. TNFα relates to various moleculCollectively, NFKB could be considered as the matchmaker between
inﬂammation, IBD, cancer and diabetes, and its wide mechanisms of
action are summarized in Fig. 4.es leading to IBD, CRC, and T2DM.
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TNFα is a cytokine produced by activated macrophages as well
as other cells. It is one of the ﬁrst cytokines to be released during
the acute inﬂammatory response. It plays a pivotal role in system-
ic inﬂammation as it induces the synthesis of C-reactive protein,
vasodilatation, and vascular permeability and helps in the recruit-
ment of inﬂammatory cells. In harmony with IL-17, TNF-α trig-
gers the expression of neutrophil-attacking chemokines CXCL1,
CXCL2 and CXCL5 which in turn increase CXCR2-dependent neu-
trophil migration to the inﬂammation site. Diapedisis is also facil-
itated through TNF-α's effect on cell adhesion molecules [15,54]
(Fig. 5).
Among the immune-regulatory factors, TNF α is increased in the
mucosa of IBD patients, and has been shown to play a central role in
the pathogenesis of the disease, and anti TNF α therapy has proven to
be beneﬁcial in the treatment of IBD [28]. In addition, TNFα activates
other signaling pathways such as NFkB and Mitogen-activated protein
kinases (MAPK) pathway, resulting in Jun N-terminal kinase (JNK)
and the activator protein 1 (AP-1) activity. Thus the sustained activity
of both NFκB and AP-1 is known to be a mediator in distinct phases of
colon carcinogenesis [11] (Fig. 5).
More than a decade ago, it was discovered that TNFα is over-
expressed in the adipose tissues of obese mice, thereby establishing a
clear link between obesity, T2DM and chronic inﬂammation [64]. Con-
sequently, as represented in Fig. 5, TNF α is a key player in IBD, CRC
and T2DM.
The association between T2DM and cancer is validated in several
studies: Orsini andWolk demonstrated fromameta-analysis of 15 stud-
ies including more than 2.5 million patients that diabetic people have
30% increased risk of developing CRC compared to non-diabetics [48].
371 million people worldwide have DM [56]. Seshasai et al. stated in a
review based on 97 prospective studies that 123,205 cases of mortality
of cancer were linked to diabetes among a total mortality of 820,900
cases. The relative risk of diabetes associated to CRC is 1.40 with 95%
conﬁdence interval (CI) [10,56].Fig. 6. The beneﬁcial effect of probiotics on T2DM, IBD and CRC. Note thatOn the other hand several studies investigated the correlation
between T2DM and IBD in 2015, SY LEE et al. showed that metformin
which is an effective widely used T2DM treatment was able to decrease
the severity of IBD and diminishes inﬂammation [31].
8. The link of microbiota to IBD, T2DM and CRC
The role of dysbiosis in the pathogenesis of IBD, CRC, and T2DM is
being strengthened by several studies and reports involving probiotics.
The term “probiotics”, meaning “for life” in Greek, was ﬁrst used in 1965
to describe any substance or organism that was beneﬁcial in promoting
microﬂoral balance in the intestinal system [9]. The Beneﬁcial role of
probiotics in IBD, CRC and T2DM was demonstrated in several studies
[3]. XuZ et al. showed that the probiotic biﬁdobacterium could signiﬁ-
cantly ameliorate the disorder of glucose and lipid metabolism [65].
Furthermore a clinical study investigated the effect of milk fermented
with Lactobacillus helveticus on blood pressure, glycemic control and
cardiovascular risk factors in T2DM using a randomized, double-
blinded, prospective, placebo-controlled study. The change in fasting
blood glucose concentration differed signiﬁcantly between the two
groups with a larger increase in the placebo group [27]. It has been
also reported that consumption of a symbiotic shake resulted in a signif-
icant decrease in fasting glycemia in T2DM patients [2] (Fig. 6).
In addition to its inhibiting effect on T2DM, existing evidence clearly
support an immunomodulatory role of probiotics in CRC, particularly its
ability tomodulate intestinal inﬂammation, awell-known risk factor for
CRC. Other studies along this line showed that the administration of L.
plantarum Lp91 signiﬁcantly reduced COX-2 and TNFα while up regu-
lated IL-10 levels in the colon tissues of mice with TNBS-induced colitis
[45]. Another treatment involving the probiotic mixture VSL#3 led
again to reduction in COX-2, NFkB, TNF-α, IL-6 and inducible nitric
oxide synthase, while increasing IL-10 and TGFβ expression in colonic
tissue of rats with dextran sulfate sodium-induced colitis [4].
Beneﬁcial effects of probiotic treatment have been observed with
the restoration of normal goblet cells numbers and stimulation of the
mucosal immune system in the patients' intestinal tract to secreteblue arrows mean induction while red arrows indicate the inhibition.
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and bacteriocidins in the colonic lumen [39].
On the other hand, increasing evidence suggests that intestinal
microbiota play a role in initiating, maintaining and determining the
severity of IBD. Such effect is limited to a continuous antigenic stimula-
tion causing chronic intestinal injury concurring to the typical alter-
ations of the gut associated lymphoid tissue associated with IBD [33].
Furthermore, molecular dynamics of dysbiosis encompass modula-
tion of genotoxic metabolites from different bacterial strains and are
able to induce CRC formation in the presence of polymorphisms
responsible of reduced activity of NOD2 [7]. Dysbiosis was proven to
exert detrimental effects on the mechanisms responsible of cellular
differentiation, apoptosis and proliferation control [6]. The great impor-
tance of colonic microbiome in CRC development is substantiated by
experiments of stool transfer from individuals with colon cancer and
healthy germ-freemice [55]. They showed that regular probiotics intake
may actively prevent the initiation and development of CRC [17].
The commonpositive effect of probiotics on T2DM, IBD and CRCmay
help in clarifying the pathological link, or links between these 3 chronic
diseases. Could it be dysbiosis?
9. Conclusion
Inﬂammation is a fundamental homeostatic response triggered by
both endogenous and exogenous noxious stimuli. It ensures the integri-
ty of the organisms. However, inﬂammation may be the mysterious
cause of several diseases including, neurodegenerative disorders,
atherosclerosis, T2DM, cancer and IBD among others. On the other
hand, IBD, CRC and T2DM are commonly occurring interrelated clinical
problems. They share a common basis inﬂuenced by disease-related in-
ﬂammation, a process characterized by up regulation of expression of
common inﬂammatory cytokines along with TGFβ, TNFα, NFKB, ROS
and other signaling molecules, leading to an imbalance in the intestinal
microbiota. The intersection between and the converging of all these
molecular pathways constitute a crosstalk leading, most likely to these
three interrelated chronic diseases. However, further clinical studies
seem necessary to clarify the complex interplay between CRC, IBD and
T2DM in addition to the role of microbiota in this loop.
A treatment that can interrupt the cross talk could probably be of
interest in managing the three disease entities and form a novel thera-
peutic target. Would probiotics interrupt the crosstalk or orient it in
the physiological direction?
References
[1] M.Z.D. Ahmed, R. Xu, Nuclear factor-kappaB in inﬂammatory bowel disease and
colorectal cancer. S –, Am. J. Dig. Dis. (2014).
[2] A. Ostadrahimi, A. Taghizadeh, M. Mobasseri, N. Farrin, L. Payahoo, Z.B. Gheshlaghi,
M. Vahedjabbari, Effect of probiotic fermented milk (Keﬁr) on glycemic control and
lipid proﬁle in type 2 diabetic patients: a randomized double-blind placebo-
controlled clinical trial, Iranian J. Public Health (2015).
[3] M. Bellavia, F. Rappa, M. Lo Bello, et al., Lactobacillus casei and Biﬁdobacterium lactis
supplementation reduces tissue damage of intestinal mucosa and liver after 2,4,6-
trinitrobenzenesulfonic acid treatment in mice, J. Biol. Regul. Homeost. Agents 28
(2) (2014) 251–261.
[4] C. Dai, C.Q. Zheng, F. Meng, Z. Zhou, L. Sang, M. Jiang, VSL#3 Probiotics Exerts the
Anti-Inﬂammatory Activity via PI3k/Akt and NF-κB Pathway in rat Model of DSS-In-
duced Colitis—Molecular and Cellular Biochemistry, Springer, 2013.
[5] C. Min, S.F. Eddy, D.H. Sherr, G.E. Sonenshein, NF-κB and Epithelial to Mesenchymal
Transition of Cancer. Journal of Cellular Biochemistry, Wiley Online Library, 2008.
[6] D. Collins, A.M. Hogan, D.C. Winter, Microbial and viral pathogens in colorectal
cancer, Lancet Oncol. 12 (5) (2011) 504–512.
[7] A. Couturier-Maillard, T. Secher, A. Rehman, et al., NOD2-mediated dysbiosis predis-
poses mice to transmissible colitis and colorectal cancer, J. Clin. Invest. 123 (2)
(2013) 700–711.
[8] D. Cannata, Y. Fierz, A. Vijayakumar, D. LeRoith, Type 2 Diabetes and Cancer:What is
the Connection? Mount Sinai Journal of Medicine, Wiley Online Library, 2010.
[9] DM Lilly, RH Stillwell. Probiotics: growth-promoting factors produced by
microorganisms—Science, 1965.
[10] D.R. Whiting, L. Guariguata, C. Weil, J. Shaw, IDF Diabetes Atlas: Global Estimates of
the Prevalence of Diabetes for 2011 and 2030—Diabetes Research and Clinical
Practice, Elsevier, 2011.[11] F. Balkwill, Tumour necrosis factor and cancer, Nat. Rev. Cancer, nature (2009).
[12] F.R. Greten, L. Eckmann, T.F. Greten, J.M. Park, Z.W. Li, M.F. Kagnoff, L.J. Egan, et al.,
IKKβ Links Inﬂammation and Tumorigenesis in a Mouse Model of Colitis-
Associated Cancer. Cell, Elsevier, 2004.
[13] G.A.P. Ganepola, J. Nizin, J.R. Rutledge, D.H. Chang, Use of blood-based biomarkers
for early diagnosis and surveillance of colorectal cancer, J. Gastrointestinal
Enterology (2014).
[14] G. Hundorfean, M.F. Neurath, J. Mudter, Functional Relevance of T Helper 17 (Th17)
Cells and the IL-17 Cytokine Family in Inﬂammatory Bowel Disease. Inﬂammatory
Bowel Diseases, Wiley Online Library, 2012.
[15] G.K. Grifﬁn, G. Newton, M.L. Tarrio, D. Bu, P. Alcaide, V. Azcutia, E.M. Garcia, et al., IL-
17 and TNF-α sustain neutrophil recruitment during inﬂammation through
synergistic effects on endothelial activation, J. Immunol. (2012).
[16] G. Monteleone, F. Pallone, C. Stolﬁ, The dual role of inﬂammation in colon carcino-
genesis, Int. J. Mol. Sci. (2012).
[17] G. Tomasello, P. Tralongo, P. Damiani, E. Sinagra, B. Trapani, M.N. Zeenny, I.H.
Hussein, A. Jurjus, A. Leone, Dismicrobism in inﬂammatory bowel disease and colo-
rectal cancer: changes in response of colocytes, World J. Gastroenterol. (2014).
[18] H. Yadav, C. Quijano, A.K. Kamaraju, O. Gavrilova, R. Malek, W. Chen, P. Zerfas,
Protection from obesity and diabetes by blockade of TGF-β/Smad3 signaling, Cell
Metabolism, Elsevier, 2011.
[19] I.A. Hajj Hussein, R. Tohme, K. Barada, M.H. Mostafa, J.N. Freund, R.A. Jurjus, W.
Karam, A. Jurjus, Inﬂammatory bowel disease in rats: bacterial and chemical inter-
action, World J. Gastroenterol. (2008).
[20] I. Andújar, M.C. Recio, R.M. Giner, E. Jovellanos, S. Laghi, B. Muguerza, J.L. Ríos, Inhi-
bition of ulcerative colitis in mice after oral administration of a polyphenol-enriched
cocoa extract is mediated by the inhibition of STAT1 and STAT3 phosphorylation in
colon cells, J. Agric. Food Chem. (2011).
[21] I. Cheng, C.P. Caberto, A.L. Jones, A. Seifried, L.R. Wilkens, F.R. Schumacher, K.R.
Monroe, Type 2 diabetes risk variants and colorectal cancer risk: the multiethnic
cohort and PAGE studies, Gut (2011).
[22] I. Crncec, P. Pathria, J. Svinka, R. Eferl, Induction of Colorectal Cancer in Mice and
Histomorphometric Evaluation of Tumors, Mouse Models of Cancer: Methods in
Molecular Biology, Springer, 2015.
[23] J.J. Kim, S. Shajib, M.M. Manocha, W.I. Khan, Investigating intestinal inﬂammation in
DSS-induced model of IBD, J. Vis. Exp. (2012).
[24] J. Massagué, TGFβ in Cancer, Cell, Elsevier, 2008.
[25] J. Meier, ASturm, Current treatment of ulcerative colitis, World J. Gastroenterol.
(2011).
[26] J. Rugtveit, E.M. Nilsen, A. Bakka, H. Carlsen, P. Brandtzaeg, H. Scott, Cytokine proﬁles
differ in newly recruited and resident subsets of mucosal macrophages from inﬂam-
matory bowel disease, Gastroenterology (1997).
[27] KD Hove, C Brøns, K Fae: rch, SS Lund, P Rossing, A Vaag Effects of 12 weeks of
treatment with fermentedmilk on blood pressure, glucose metabolism andmarkers
of cardiovascular risk in patients with type 2 diabetes: a randomised double-blind
placebo-controlled study—Eur. J. Endocrinol., 2015.
[28] K.A. Papadakis, S.R. Targan, Role of cytokines in the pathogenesis of inﬂammatory
bowel disease, Annu. Rev. Med. (2000).
[29] K.J. Maloy, F. Powrie, Intestinal homeostasis and its breakdown in inﬂammatory
bowel disease, Nature (2011).
[30] L.A. Feagins, Role of Transforming Growth Factor-β in Inﬂammatory Bowel Disease
and Colitis-Associated Colon Cancer—Inﬂammatory bowel diseases, Wiley Online
Library, 2010.
[31] Lee, S.H. Lee, E.K. Kim, J.K. Kim, D.Y. Shin, M.L. Cho, Metformin ameliorates inﬂam-
matory bowel disease by suppression of STAT3 signaling pathway and regulation
of the Th17/Treg balance (THER3P. 1001), J. Immunol. (2015).
[32] L Hawinkels, M Paauwe, HW Verspaget, E Wiercinska, JM van der Zon, K van der
Ploeg, PJ Koelink, et al.. Interaction with colon cancer cells hyperactivates TGF-β
signaling in cancer-associated ﬁbroblasts—Oncogene, 2014.
[33] C.L. Maynard, C.O. Elson, R.D. Hatton, et al., Reciprocal interactions of the intestinal
microbiota and immune system, Nature 489 (7415) (2012) 231–241.
[34] M.C. Mattar, D. Lough, M.J. Pishvaian, A. Charabaty, Current management of inﬂam-
matory bowel disease and colorectal cancer, Gastrointest. Cancer Res. (2011).
[35] M.G. Laukoetter, P. Nava, A. Nusrat, Role of the intestinal barrier in inﬂammatory
bowel disease, World J. Gastroenterol. (2008).
[36] M.S.H. Akash, K. Rehman, S. Chen, Role of Inﬂammatory Mechanisms in Pathogene-
sis of Type 2 Diabetes Mellitus. Journal of Cellular Biochemistry, Wiley Online
Library, 2013.
[37] M.S. Hayden, S. Ghosh, Shared Principles in NF-κB Signaling. Cell, Elsevier, 2008.
[38] M.R. Rubin, A.B. Goldﬁne, D.J. McMahon, D.S. Donovan, S. Cremers, E. Dworakowski,
E.J. Schaefer, et al., Effects of the Anti-Inﬂammatory Drug Salsalate on Bone Turnover
in Type 2 Diabetes Mellitus—Endocrine, Springer, 2015.
[39] Y. Nami, N. Abdullah, B. Haghshenas, et al., Assessment of probiotic potential and
anticancer activity of newly isolated vaginal bacterium lactobacillus plantarum
5BL, Microbiol. Immunol. 58 (9) (2014) 492–502.
[40] N. Erez, M. Truitt, P. Olson, D. Hanahan, Cancer-Associated Fibroblasts are Activated
in Incipient Neoplasia to Orchestrate Tumor-Promoting Inﬂammation in an NF-κB-
Dependent Manner, Cancer Cell, Elsevier, 2010.
[41] P.J. Basso, M.T.C. Fonseca, G. Bonfá, V.B.F. Alves, H. Sales-Campos, V. Nardini, C.R.B.
Cardoso, Association among genetic predisposition, gut microbiota, and host im-
mune response in the etiopathogenesis of inﬂammatory bowel disease, Braz. J.
Med. Biol. Res. (2014).
[42] R. Atreya, J. Mudter, S. Finotto, J. Müllberg, T. Jostock, S. Wirtz, M. Schütz, et al.,
Blockade of interleukin 6 trans signaling suppresses T-cell resistance against
apoptosis in chronic intestinal inﬂammation: evidence in Crohn disease and exper-
imental colitis in vivo, Nat. Med. (2010).
24 A. Jurjus et al. / BBA Clinical 5 (2016) 16–24[43] R.B. Sartor, Pathogenesis and immune mechanisms of chronic inﬂammatory bowel
diseases, Am. J. Gastroenterol. (1997).
[44] R.J. Xavier, D.K. Podolsky, The pathogenesis of inﬂammatory bowel disease, Nature
(2007).
[45] R.K. Duary, M.A. Bhausaheb, V.K. Batish, S. Grover, Anti-Inﬂammatory and Immuno-
modulatory Efﬁcacy of Indigenous Probiotic Lactobacillus Plantarum Lp91 in Colitis
Mouse Model. Molecular Biology Reports, Springer, 2012.
[46] R. Thoreson, J.J. Cullen, Pathophysiology of Inﬂammatory Bowel Disease: An
Overview. Surgical Clinics of North America, Elsevier, 2007.
[47] S.C. Gupta, J.H. Kim, S. Prasad, B.B. Aggarwal, Regulation of Survival, Proliferation,
Invasion, Angiogenesis, and Metastasis of Tumor Cells Through Modulation of
Inﬂammatory Pathways by Nutraceuticals. Cancer Metastasis Reviews, Springer,
2010.
[48] SC Larsson, N Orsini, AWolk. Diabetes mellitus and risk of colorectal cancer: a meta-
analysis—J. Natl. Cancer Inst. 2005.
[49] S.E. Erdman, T. Poutahidis, Roles for inﬂammation and regulatory T cells in colon
cancer, Toxicol. Pathol. (2010).
[50] S.E. Kahn, The Relative Contributions of Insulin Resistance and Beta-Cell Dysfunction
to the Pathophysiology of Type 2 Diabetes, Diabetologia, Springer, 2003.
[51] S. Fischbach, G.K. Gittes, The role of TGF-β signaling in β-cell dysfunction and type 2
diabetes: a review, J. Cytol. Histol. (2014).
[52] S. Grivennikov, E. Karin, J. Terzi, D. Mucida, G.Y. Yu, S. Vallabhapurapu, J. Scheller, IL-
6 and Stat3 Are Required for Survival of intestinal epithelial cells and development
of Colitis-Associated Cancer Cancer cell, Elsevier, 2009.
[53] S. Hong, H.J. Lee, S.J. Kim, K.B. Hahm, Connection between inﬂammation and
carcinogenesis in gastrointestinal tract: focus on TGF-β signaling, World J.
Gastroenterol. (2010).
[54] S.M. Vieira, H.P. Lemos, R. Grespan, M.H. Napimoga, D. Dal-Secco, A. Freitas, T.M.
Cunha, et al., A Crucial Role for TNF-α in Mediating Neutrophil Inﬂux Induced
by Endogenously Generated or Exogenous Chemokines, KC/CXCL1 and LIX/
CXCL5—British journal of Pharmacology, Wiley Online Library, 2009.[55] I. Sobhani, V. Jarrousse, S. Guilemeau, et al., Colon cancer patients' microbiome in-
duces intestinal precancerous change in germ-free mice, Gut 60 (3) (2011) A1.
[56] S.R. Seshasai, S. Kaptoge, A. Thompson, E.D. Angelantonio, P. Gao, N. Sarwar, P.H.
Whincup, et al., Diabetes mellitus, fasting glucose, and risk of cause-speciﬁc death,
N. Engl. J. Med. 364 (2011) 829–841.
[57] S.U. Seo, G.Y. Chen, G. Núñez, N. Kamada, Role of the gut microbiota in immunity
and inﬂammatory disease, Nat. Rev. Immunol. (2013).
[58] T. Kühbacher, S. Schreiber, U.R. Fölsch, Ulcerative Colitis: Conservative Management
and Long-Term Effects. Langenbeck's Archives of Surgery, Springer, 2004.
[59] V.T. Chandrasekar, N. Venu, So What Is Crohn's disease and Ulcerative Colitis? Path-
ophysiology of Crohn's disease and Ulcerative Colitis. Inﬂammatory Bowel Disease,
Springer, 2015.
[60] W. Strober, F. Zhang, A. Kitani, I. Fuss, S. Fichtner-Feigl, Pro-inﬂammatory cytokines
underlying the inﬂammation of Crohn's disease, Curr. Opin. Gastroenterol. (2010).
[61] X.H. Feng, R. Derynck, Speciﬁcity and versatility in TGF-β signaling through Smads,
Rev. Cell Dev. Biol. (2005).
[62] X. Wu, V.S. Conlin, V. Morampudi, N.R. Ryz, Y. Nasser, G. Bhinder, K.S. Bergstrom,
et al., Vasoactive intestinal polypeptide promotes intestinal barrier homeostasis
and protection against colitis in mice, PLoS One (2015).
[63] Y. Ben-Neriah, M. Karin, Inﬂammation Meets Cancer, with NF-[Kappa] B as the
Matchmaker—Nature Immunology, 2011.
[64] Z. Liu, R.S. Brooks, E.D. Ciappio, S.J. Kim, J.W. Crott, G. Bennett, A.S. Greenberg, et al.,
Diet-Induced Obesity Elevates Colonic TNF-α in Mice and is Accompanied by an Ac-
tivation of Wnt Signaling: A Mechanism for Obesity-Associated Colorectal
Cancer—The Journal of Nutritional Biochemistry, Elsevier, 2012.
[65] Z. Xu, R. Wang, Y. Yang, R. Dai, J. Shang, Q. Yu, Intervention Effect of Probiotic
Biﬁdobacterium on Type 2 Diabetes Mellitus Rats—Journal of Hygiene Research,
2014.
